Stability a strength of filtration device

Article

Performance compares favourably with trabeculectomy, in physician's experience

A glaucoma filtration device (Ex-PRESS, Alcon Laboratories) has several advantages - such as greater stability during and after surgery - that compare favourably with trabeculectomy, according to a surgeon who has performed a number of procedures using this technique.

Stability is also enhanced postoperatively because of the design of this device, which is not valved. It has a constant, controlled internal lumen of 50 µm that provides a degree of resistance to aqueous outflow as well as a greater measure of control over hypotony, Dr Pickering explained, adding that the chamber tends to stay deeper even at low pressures.

Overall, the results tend to be more stable and more predictable than when performing trabeculectomy.

"It's trying in a way to accomplish the ultimate goal, which is making glaucoma filtering surgery more of a standardized procedure," said Dr Pickering, who is in practice at the Glaucoma Center of San Francisco. "It hasn't completely achieved that goal, but it's a step in that direction."

She also mentioned that because implantation of the filtration device is a refinement of trabeculectomy, which is an established technique, the learning curve is short.

"You already know how to do it. You're just adding one step and taking away two others," Dr Pickering explained.

A further advance of the shunt is that it reduces inflammation because implantation under the sclera does not require iridectomy or sclerectomy. The risk of inflammation is also lower because tissue is not removed and there is less chance of hyphema or pigment release.

The shunt was invented in 1996 by Ira Yaron, chief executive officer of Optonol, which was subsequently acquired by Alcon. The device received FDA approval in 2002. It was originally designed to be implanted under the conjunctiva, but a technique to implant it under the scleral flap was introduced in 2003.

Although not a new device, some glaucoma surgeons remain reluctant to use it or skeptical of claims of its advantages, Dr Pickering said. She suggested that in many cases physicians simply have preferred practice patterns that would be disrupted by adopting the shunt technique, while others are concerned about the additional cost of using this drainage device as opposed to performing a straightforward trabeculectomy. Other physicians have suggested the need for more data; although small studies of this drainage device have been performed, there has not been a large, randomized, controlled trial.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.